Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetesPRNewsWire • 10/15/25
New to Investing? These Are 3 Solid Blue Chip Stocks You Can Build Your Portfolio AroundThe Motley Fool • 10/15/25
1 Reason Eli Lilly (LLY) Is One of the Best Healthcare Stocks You Can Buy TodayThe Motley Fool • 10/15/25
Independence Bank of Kentucky Buys Another $3.1 Million Eli Lilly (NYSE: LLY) SharesThe Motley Fool • 10/14/25
Healthcare Opportunities And Risks Collide For Direxion's Eli Lilly-Focused ELIL, ELIS ETFsBenzinga • 10/13/25
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Oct 2025)24/7 Wall Street • 10/13/25
Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual MeetingPRNewsWire • 10/13/25
AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025?Zacks Investment Research • 10/09/25
Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity MarketThe Motley Fool • 10/09/25